HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) administered via intramyocardial injection during coronary artery bypass graft surgery.” Heart failure (HF) is a significant public health issue, affecting at least 7 million patients in the US and approximately 65 million globally. Due to its increasing incidence and prevalence among the elderly, heart...